SIP
AEGR

Stoneridge Investment Partners’s Aegerion Pharmaceuticals AEGR Stock Holding History

Stoneridge Investment Partners’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-56,471
Closed -$1.89M – 300
2014
Q3 		$1.89M Buy
+56,471
New +$1.75M 0.28% 120

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Stoneridge Investment Partners's AEGR Position: Q4 2014 in Review

Stoneridge Investment Partners sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2014, closing a stake of 56,471 shares — an estimated $1.89M sold.

Stoneridge Investment Partners first reported a position in AEGR in Q3 2014 and held it in 1 quarter. The position peaked at $1.89M in Q3 2014. 95 funds tracked by Wall St. Rank hold AEGR as of Q4 2014.

  • Stoneridge Investment Partners reported no remaining Aegerion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Stoneridge Investment Partners sold 56,471 Aegerion Pharmaceuticals shares in Q4 2014, an estimated $1.89M.
  • Stoneridge Investment Partners first reported a position in Aegerion Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Stoneridge Investment Partners's Aegerion Pharmaceuticals position peaked at $1.89M in Q3 2014.
  • 95 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2014.

Based on Stoneridge Investment Partners's 13F filing for Q4 2014, filed 26 Jan 2015.